

Mr Mark Reid

14 September 2018

Supplementary Submission

Response to QVFA Supplementary submission 16.8

Ms Lyn Beverley
Committee Secretary
Senate Foreign Affairs, Defence and Trade references Committee
PO Box 6100 parliament House
Canberra ACT 2600

Dear Lyn,

Re Senate Inquiry – Use of the Quinoline anti-malarial drugs Mefloquine and Tafenoquine in the Australian Defence Force. – Supplementary Submission made by Major McCarthy (retired)

I understand Major McCarthy (retired) has made another supplementary submission in relation to my oral testimony presented to the Committee on the 30th August 2018. The date of Major McCarthy (retired) new submission is the 13th September 2018 after he made the tweet (copied below on the 11th September 2018).

Allegation of misleading the Committee about “Cooperative Research and Development Agreements”:

- To my knowledge, the US Federal Technology Transfer Act of 1986 ((p.l. 99-502) enables US government departments to form cooperative research and development agreements (CRADA) with commercial parties.
- In kind (but not direct) funding is permitted to support CRADA partners but the government co-development partner cannot give money directly to a CRADA partner.
- Therefore, my oral testimony to Senator O’Sullivan stands. The US government cannot pay money to 60P “to do this work” under the US Federal Technology Transfer Act of 1986.
- 60 degrees Pharmaceuticals LLC and the US Army Medical Materiel Development Activity are CRADA partners as evidenced by the CRADA obtained by Dr. Remington Nevin under a Freedom of Information (FOI) request.
- I believe a copy of this 60P-USAMMDA CRADA has been submitted to the Committee by Major McCarthy (retired) on the 6th September 2018.
- As this is a Sponsor question, I believe it appropriate to refer the Committee to any relevant testimony from Dr. Dow.
- Incidentally, a CRADA between Bristol Myers Squibb and the US National Cancer Institute (NCI) was agreed in the 1980s and led to the commercialisation of Taxol® (paclitaxel) for ovarian and breast cancer. Over > 1 million cancer patients have been treated with this drug developed under this CRADA including Australian citizens as Taxol® was approved by the Australian TGA in September 2004.
- <https://techtransfer.cancer.gov/aboutttc/successstories/taxol>
- <https://www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2010-PI-02667-3&d=201809141016933>

Replying to [@mefloq_vets](#) [UK](#) [@JaneCQuinn1](#) and 10 others

It's simple. [@reid99mark](#) has deliberately misled [@AuSenate](#) . Lock him up please. He cares not for our laws and he is an external threat to the country. [#TafenoquineRC](#) [#Mefloquine@AmandaRishworth](#) [@c_otoole@AdamBandtpic.twitter.com/SQ6BrGL9W0](#)



Senator O'SULLIVAN: *I just want to try and get these relationship lines, because they're important, as you'd appreciate, as we give weight to the various testimonies that are provided. Is it the case that the US military, using public funding, socialised funding, paid 60 Degrees to embark on this journey?*

Mr Reid : *No. They're not allowed to.*

~ Hansard, 30 August 2018

The screenshot shows the 'INVESTORS' page of the 60 Degrees Pharma website. The header features the company logo and a city skyline. The main heading is 'INVESTORS: CAPTURE NEW, UNADDRESSED MARKET OPPORTUNITIES'. Below this, there are three sections: '60° PHARMACEUTICALS (60P): A TWO-PRONGED MISSION FOR INVESTORS', 'INVESTING IN AN ESTABLISHED MARKET', and '60P: EXCLUSIVE RIGHTS TO DEVELOP TAFENOQUINE (FOR MALARIA PREVENTION)'. Each section contains bullet points detailing the company's mission and partnerships.

INVESTORS: CAPTURE NEW, UNADDRESSED MARKET OPPORTUNITIES

60° PHARMACEUTICALS (60P): A TWO-PRONGED MISSION FOR INVESTORS

- Commitment to developing new therapies for the treatment and prevention of tropical diseases
- Privately held company that is interested in a healthy return on investment

INVESTING IN AN ESTABLISHED MARKET

A tremendous investment opportunity exists due to the ineffective preventative malaria therapies currently on the market along with expanding disease risks. This calls for more effective and efficient prevention therapies.

60P: EXCLUSIVE RIGHTS TO DEVELOP TAFENOQUINE (FOR MALARIA PREVENTION)

- Secured research and licensing agreements, sponsorships rights, and use patents with the U.S. Army
- Ongoing U.S. Army-support \$US18+ million for development program

COMPETITIVE ADVANTAGES IN DENGUE FEVER TREATMENT

- Celgosivir and Modipafant: Decreasing disease burden
- Targeted vaccine will be to prevent or reduce the incidence and duration of illness and/or

"Ongoing U.S. Army support - \$18+ million for development program."

~ 60 Degrees Pharma website

2 replies 5 retweets 4 likes

2
5
5
4
4